Last reviewed · How we verify
ODV 100 mg
At a glance
| Generic name | ODV 100 mg |
|---|---|
| Sponsor | Janssen Research & Development, LLC |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Nausea
- Nasopharyngitis
- Pyrexia
- Somnolence
- Headache
- Dizziness
- Weight decreased
Key clinical trials
- A Study of MD-120 in Patients With Depression (PHASE3)
- Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) vs. Escitalopram in Postmenopausal Women (PHASE3)
- Adjunctive Mixed Salts Amphetamine for Depressed Adults With Incomplete Response to Current Antidepressant Therapy (PHASE4)
- Tracking Response to Antidepressants in Advance of Investigational Trials
- Efficacy of SNRI Treatment on Prefrontality in Patients With GAD and Other Comorbities (PHASE4)
- Desvenlafaxine in Opioid-Dependent Patients (PHASE4)
- Study Evaluating Long-Term Safety of Desvenlafaxine Succinate Sustained Release With Japanese Adult Subjects in Major Depressive Disorder (MDD) (PHASE3)
- Study to Investigate the Pharmacokinetics, Safety and Tolerability of Odalasvir and AL-335 in Healthy Japanese Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |